Tailored insights, in real-time, from your global clinical experts.
ESMO Findings for mCRPC: What This Means for Clinical Findings
About This Intelligence Report
Initial treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) have revolved around the use of chemotherapy and androgen deprivation therapy (ADT), largely remaining the same for years.
Now, for the first time in about a decade, we have the promise of a new regimen that can further improve clinical outcomes of these patients. The team behind NoeticInsight moved quickly to gather thoughts on the future of mCRPC.
Through our virtual blinded platform, we easily connected with leaders in the field of prostate cancer who were able to share their honest and robust opinions with us through our unique approach.
Contents
- Key Findings
- Unmet Needs
- Expert Impressions from the Data
- Upcoming Studies to Watch
Complete the brief form to receive your copy of this valuable report to help solidify your strategy.
